The Pharma Data

MARCH 8, 2022

The virus carries the information to produce a series of proteins, capable of inhibiting antiviral recognition systems of the infected cell. Actually, these systems could identify viral genetic material (here: Ribonucleic acids/RNAs) and sound the alarm. Camouflage protects virus from immune system.

Immune Response 52

Immune Response RNA Protein Genetics 52

Delveinsight

AUGUST 26, 2021

Shape’s RNA editing technologies can modify the RNA sequence, which makes the body’s protein building blocks. This system is designed to deliver RNA editing technology or other payloads directly to particular body areas, such as the nervous system or muscle. The study is set to conclude in the fall.

Vaccination 98

Vaccination Vaccine Gene Therapy RNA 98

The Pharma Data

DECEMBER 3, 2020

S-Trimer adjuvanted with GSK’s pandemic adjuvant system induced neutralizing antibody titers (seroconversion) in 100% of participants at the selected 9 µg S-Trimer dose in both adult and elderly groups, with geometric mean titers (GMT) greater than 1:1,800.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

XTalks

NOVEMBER 30, 2023

Its mechanism of action involves blocking the protein shell (capsid) of the HIV-1 virus, disrupting multiple crucial stages of the viral lifecycle. Over 26 weeks of Sunlenca combined with other antiretroviral drugs, 81 percent of participants achieved HIV RNA suppression, reaching levels low enough to be considered undetectable.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

pharmaphorum

OCTOBER 6, 2020

These studies suggest BNT162b2 triggers the production of neutralising antibodies and T-cells that target SARS-CoV-2, the coronavirus that causes COVID-19. BNT162b2 is being tested in a global phase 3 study ongoing at more than 120 clinical sites worldwide including the US, Brazil, South Africa and Argentina.

Vaccination 59

Vaccination Vaccine RNA Immune Response 59

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. Preclinical data showed that two immunizations of the mRNA vaccine induced high neutralizing antibody levels that are comparable to the upper range of those observed in infected humans.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.

Vaccination 52

Vaccination Vaccine Protein Immune Response 52

pharmaphorum

SEPTEMBER 22, 2022

When exposed to a virus, one’s immune system develops antibodies in response to foreign antigens, with or without a vaccine. However, a vaccine trains the immune system to recognise that familiar virus and kill it more rapidly. One arm of the immune system triggers antibodies, and the other triggers T-cells.

Vaccination 97

Vaccination Vaccine Antibody Clinical Trials 97

pharmaphorum

JULY 6, 2021

Nina Garrett, R&D director at Abingdon Health discusses the key role antibody testing is playing in the pandemic and how an integrated approach with vaccines could help normal life resume. The three most common types of testing, PCR testing, antigen testing and antibody testing, have quickly become common terms in everyone’s vocabulary.

Antibody 111

Antibody Immune Response Protein Vaccination 111

The Pharma Data

JANUARY 31, 2021

Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. EMERYVILLE, Calif. and CHENGDU, China , Feb.

Vaccination 52

Vaccination Vaccine Trials Protein 52

pharmaphorum

JANUARY 17, 2023

Once its potential as a means of stimulating an immune response had been established, attention quickly turned to where else the technology could provide a therapeutic solution. As it stands, mRNA vaccines and therapeutics can only provide benefits if they can reach the living cells and be processed into protein.

Vaccination 97

Vaccination Vaccine In-Vivo In-Vitro 97

Roots Analysis

OCTOBER 30, 2023

In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions.

RNA 40

RNA Vaccination Vaccine Development 40

The Pharma Data

DECEMBER 10, 2020

The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The goal of targeting both S and N was to both activate virus-specific T cells and generate anti-SARS-CoV-2-neutralizing antibodies. This press release features multimedia.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

JULY 6, 2021

Fitusiran is an investigational, subcutaneously administered small interference RNA therapy in development for the treatment of people with hemophilia A or B, with or without inhibitors and has the potential to transform treatment as it would be the only prophylactic therapy with as few as six injections per year. ePoster Abstract # OC48.2

Protein 52

Protein RNA Marketing Development 52

Find Me Cure

OCTOBER 13, 2019

HER2 is a protein that plays an important role in cancer cell growth and is found on the surface of cancer cells in a very high quantity in about 10-20% of breast cancers. There are antibody drugs targetting those cells that are already FDA approved and there are antibody drugs still in trials.

Development 52

Development DNA Clinical Trials Clinical Trials 52

The Pharma Data

MAY 17, 2021

The investigational COVID-19 vaccine uses the same recombinant protein-based technology as one of Sanofi’s seasonal flu vaccines, along with GSK’s established pandemic adjuvant technology. The interim results from the phase 2 trial on the vaccine, published today, on the contrary, showed a “ strong neutralizing antibody response” ?

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

The Pharma Data

JULY 6, 2021

But HIV’s ability to mutate isn’t unique among RNA viruses – most viruses develop mutations, or changes in their genetic code, over time. ” In the same time period, mRNA vaccines were being deployed and immune responses to those vaccines were being studied.

Vaccination 52

Vaccination Vaccine Research Immune Response 52

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

Protein 59

Protein Antibody Engineer Scientist 59

XTalks

JUNE 5, 2023

Abrysvo is an unadjuvanted vaccine and is composed of two preF proteins selected to optimize protection against RSV A and B strains. “A RSV belongs to the family of negative-strand RNA viruses and was first identified in 1955. The genetic material of RSV (respiratory syncytial virus) encodes 11 proteins. billion by 2028.

Vaccination 98

Vaccination Vaccine FDA Approval Protein 98

The Pharma Data

AUGUST 3, 2021

Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. whose proprietary peptide- and protein-engineering platform is used to identify and synthesize molecules that can sense glucose or other endogenous modulators of protein activity.

Antibody 52

Antibody Sales Development Production 52

The Pharma Data

JANUARY 21, 2021

Luckily, the new variants still rely on the coronavirus’ “spike protein” to infect cells, and the two COVID vaccines now on the U.S. market specifically target the spike protein to prevent transmission, explained Dr. Kathryn Edwards, scientific director of the Vanderbilt University Vaccine Research Program in Nashville.

Vaccination 52

Vaccination Vaccine Protein Immune Response 52

Drug Discovery World

FEBRUARY 6, 2023

We use MA plots, heatmaps, pathway maps, and trend plots of clusters (clusters for features with correlated response) as shown in Figure 2 but also UpSet plots, advanced Venn diagrams, to summarise overlap in differential features across multiple timepoints and study arms.

Big Data 52

Big Data RNA Bioinformatics Vaccination 52

Drug Discovery World

JANUARY 4, 2023

The researchers used high-dimensional immune profiling and single-cell RNA sequencing to study how the TIME is affected by a variety of immunotherapies. They identified specific immune checkpoint proteins, 41BB and LAG, that were highly expressed in exhausted T cells. .

Immune Response 52

Immune Response Protein Antibody Research 52

Drug Discovery World

SEPTEMBER 6, 2022

However, whilst these comments largely reflect a positive outlook for investment in the industry, financing in Q1 of 2022 largely remained level with the backend of last year, hovering just over $500 million according to American Society of Gene & Cell Therapy’s (ASGCT) – Gene, Cell, & RNA Therapy Landscape Q1 report. .

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

The Pharma Data

JUNE 25, 2021

The vaccine candidate chosen for first clinical development, CVnCoV, is an optimized, non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus, and formulated within Lipid Nanoparticles (LNPs). Phase 1 and 2a clinical trials of CVnCoV began in June and September 2020, respectively.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

Drug Discovery World

MAY 30, 2023

From antibody-drug conjugates and RNA, to CRISPR and CAR-T therapy, DDW asked the drug discovery industry what the most important development in oncology over the last five years has been. At PhoreMost, we have been particularly excited about the emergence of targeted protein degradation (TPD) as a new therapeutic modality.

Research 52

Research Drugs Protein RNA 52

The Pharma Data

JUNE 26, 2021

Sanofi Pasteur, the vaccines global business unit of Sanofi and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have initiated a Phase 1 clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza. We look forward to sharing initial results by year-end. ”. “

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

XTalks

MARCH 10, 2021

While molecular PCR-based tests remain the gold standard for the detection of SARS-CoV-2 viral RNA, rapid antigen tests are useful for screening purposes. Adding to the testing repertoire is the first T cell-based test that can detect previous infection, akin to antibody tests. 1. First T-Cell Test from Adaptive Biotechnologies.

Protein 98

Protein RNA Antibody Production 98

Drug Discovery World

OCTOBER 17, 2023

Today, spatial omics technologies enable imaging-based identification of cells in their native tissue context while simultaneously detecting hundreds of RNAs or tens of protein markers in the same cells. Let’s take CAR T cells as an example. RA: What have been some recent insights discovered using spatial biology?

Gene Expression 52

Gene Expression Drugs Protein Gene 52

The Pharma Data

DECEMBER 27, 2020

Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study of monoclonal antibody VIR-7831 for hospitalized adults with COVID-19. Galidesivir is a broad-spectrum antiviral, an adenosine nucleoside analog that blocks viral RNA polymerase. Here’s a look. COVID-19-Related. Non-COVID-19-Related.

Trials 52

Trials Antibody Gene Therapy Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

JANUARY 13, 2021

The vaccine produced an immune response of all 805 clinical trial participants within two months of inoculation, according to results published Jan. The new vaccine is made up of a deactivated cold virus into which scientists cut-and-paste a genetic version of the “spike” protein used by the coronavirus to infect cells.

Vaccination 40

Vaccination Vaccine Trials Immune Response 40

Drug Discovery World

APRIL 12, 2023

According to a McKinsey & Company article 2 , new drug modalities (such as RNA therapeutics, protein degraders, cyclopeptides, ADCs, cell and gene therapies) have almost doubled from 11% to 21% of the drug pipeline. For some pharmaceutical companies, like AstraZeneca 3 , 30% of their early pipeline consists of new drug modalities.

Development 52

Development In-Vivo Drugs In-Vitro 52

Drug Discovery World

JANUARY 20, 2023

According to a McKinsey & Company article 2 , new drug modalities (such as RNA therapeutics, protein degraders, cyclopeptides, ADCs, cell and gene therapies) have almost doubled from 11% to 21% of the drug pipeline. For some pharmaceutical companies, like AstraZeneca 3 , 30% of their early pipeline consists of new drug modalities.

Development 52

Development In-Vivo Drugs In-Vitro 52

Pfizer

NOVEMBER 2, 2022

The first participant has been dosed in a Phase 1 trial evaluating the safety, tolerability, and immunogenicity of a nucleoside-modified RNA (modRNA)-based combination vaccine approach. Hemagglutinin is a surface protein of the influenza virus which plays a role in the initiation of infection. COMIRNATY® (COVID-19 Vaccine, mRNA).

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85